-
May 7: The Delphi Panel—From Discord to Actionable HEOR Insights - In Person at ISPOR 2023
-
May 7: Introduction to Health Economics and Outcomes Research - In Person at ISPOR 2023
-
ISPOR 2023
, Boston, MA | USA
Join global healthcare leaders as they convene at ISPOR 2023, the leading global conference for Health Economics and Outcomes Research (HEOR) May 7-10, in-person and virtually for discussion and dissemination of the latest trends in healthcare. This must-attend event provides you with dedicated opportunities to network in-person and virtually with your peers, HEOR experts, and thought leaders and to discuss with a global audience how we establish, incentivize, and share value sustainable for health systems, patients, and technology developers.
-
HEOR Theater: ISPOR Special Interest Groups-Get Involved and Further Your Knowledge
-
April 26-27: Introduction to Use of Electronic Health Record Data for Health Technology Assessment- Virtual
-
Introduction to Open-Source Modeling: R We There Yet?
-
April 10-11: Meta-Analysis and Systematic Reviews in Comparative Effectiveness Research- Virtual
-
Health Equity in HEOR: Past, Present and Future Research Implications
-
March 29-30: Cost-Effectiveness Analysis Alongside Clinical Trials- Virtual
-
HEOR Theater: Student and New Professional Day
-
March 15-16: Bayesian Analysis–An Introduction- Virtual
-
March 8-9: Advanced Patient-Reported Outcomes- Virtual
-
FDA Patient-Focused Drug Development (PFDD) Guidance - Part 2
-
March 1-2: Introduction to Modeling- Virtual
-
HEOR Theater - HTA Implementation in the MEA Region – an Overview From WHO and Country Updates
-
Improving Treatment Access and Outcomes by Integrating Social Determinants of Health Data With Real-World Evidence
-
Preventing, Detecting, and Analyzing Data From Suspected Fraudulent Respondents in Online Surveys, With Examples From Health Preference Studies
-
February 13-16: Introduction to Health Economics and Outcomes Research- Virtual
-
Digital Endpoint Adoption: the How, What and Why
-
FDA Patient-Focused Drug Development (PFDD) Guidance - Part 1